Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheela Kolluri

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
The Journal of Clinical Psychiatry|July 17, 2012
Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trialsElizabeth Pappadopulos, John W Newcomer, Sheela Kolluri
Human Psychopharmacology|June 4, 2011
Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studiesCedric O'Gorman, Shitij Kapur, Sheela Kolluri, et al.
The Australian and New Zealand Journal of Psychiatry|July 20, 2010
Meta-analysis of relapse prevention antidepressant trials in depressive disordersPaul Glue, Mary Rocco Donovan, Sheela Kolluri, et al.
Journal of Affective Disorders|July 21, 2009
Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysisMary Rocco Donovan, Paul Glue, Sheela Kolluri, et al.
The AAPS Journal|January 5, 2022
Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a ReviewSheela Kolluri, Jianchang Lin, Rachael Liu, et al.
Journal of Clinical Psychopharmacology|June 23, 2012
Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?Ilise Lombardo, Gary Sachs, Sheela Kolluri, et al.
Journal of Clinical Psychopharmacology|April 24, 2013
Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophreniaKeming Gao, Elizabeth Pappadopulos, Onur N Karayal, et al.
The American Journal of Psychiatry|April 17, 2008
A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depressionBrendon Binneman, Douglas Feltner, Sheela Kolluri, et al.
Journal of Clinical Psychopharmacology|November 18, 2008
An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorderSheldon H Preskorn, Bryan Baker, Sheela Kolluri, et al.
The International Journal of Neuropsychopharmacology|June 28, 2015
Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating ScalesChristian G Widschwendter, Onur N Karayal, Sheela Kolluri, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
The Journal of Clinical Psychiatry|July 17, 2012
Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trialsElizabeth Pappadopulos, John W Newcomer, Sheela Kolluri
Human Psychopharmacology|June 4, 2011
Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studiesCedric O'Gorman, Shitij Kapur, Sheela Kolluri, et al.
The Australian and New Zealand Journal of Psychiatry|July 20, 2010
Meta-analysis of relapse prevention antidepressant trials in depressive disordersPaul Glue, Mary Rocco Donovan, Sheela Kolluri, et al.
Journal of Affective Disorders|July 21, 2009
Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysisMary Rocco Donovan, Paul Glue, Sheela Kolluri, et al.
The AAPS Journal|January 5, 2022
Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a ReviewSheela Kolluri, Jianchang Lin, Rachael Liu, et al.
Journal of Clinical Psychopharmacology|June 23, 2012
Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?Ilise Lombardo, Gary Sachs, Sheela Kolluri, et al.
Journal of Clinical Psychopharmacology|April 24, 2013
Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophreniaKeming Gao, Elizabeth Pappadopulos, Onur N Karayal, et al.
The American Journal of Psychiatry|April 17, 2008
A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depressionBrendon Binneman, Douglas Feltner, Sheela Kolluri, et al.
Journal of Clinical Psychopharmacology|November 18, 2008
An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorderSheldon H Preskorn, Bryan Baker, Sheela Kolluri, et al.
The International Journal of Neuropsychopharmacology|June 28, 2015
Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating ScalesChristian G Widschwendter, Onur N Karayal, Sheela Kolluri, et al.
Pageof 2